KYNB Kyntra Bio
Price Chart
Executive Summary
Kyntra Bio reported Q1 2026 revenue of $3.7M (above $1.6M consensus) but EPS of -$3.74 missed the -$3.35 consensus by 11.6%. The company highlighted steady enrollment in its Phase 2 FG-3246 trial (interim analysis on track for Q4 2026) and finalizing the Phase 3 roxadustat protocol for LR-MDS. Cash of $100.3M provides runway into 2028, but the EPS miss and ongoing operating losses temper the positive pipeline updates.
Actionable Insight
The revenue beat and narrowing loss are positive, but the EPS miss and pre-revenue pipeline stage keep the stock range-bound. Key catalysts are the FG-3246 interim analysis in Q4 2026 and roxadustat Phase 3 start in H2 2026 — traders should watch for enrollment updates and FDA feedback on the roxadustat protocol.
Key Facts
- Q1 2026 total revenue $3.7M vs $2.7M YoY (above $1.6M consensus)
- GAAP EPS -$3.74 vs consensus -$3.35 (miss by 11.6%)
- Net loss from continuing ops $15.1M vs $16.8M YoY (narrower loss)
- Cash, equivalents, investments, and AR of $100.3M as of March 31, 2026
- Phase 2 FG-3246 mCRPC trial interim analysis on track for Q4 2026
- Phase 3 roxadustat protocol for LR-MDS being finalized; trial initiation H2 2026
- Cash runway expected into 2028
Financial Impact
Revenue beat of $2.1M vs consensus; EPS miss of $0.39 vs consensus; operating loss narrowed by $1.1M YoY
Risk Factors
- EPS miss of 11.6% vs consensus could pressure the stock near-term
- Pre-revenue pipeline with no approved products in the US
- Dependence on FG-3246 Phase 2 data and roxadustat regulatory path
- Negative stockholders' equity of -$43.8M and total deficit of -$30.8M
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292303 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
8-K
| — | awaiting T+5 | — | — |
|
May 11, 2026
29d ago
|
Press Release
| $7.23 $6.83 | ▼ −5.47% | ▼ −5.54% | $6.69 (−7.40%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $7.37 $6.75 | ▲ +8.41% | ▲ +5.76% | $6.69 (+9.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access